Literature DB >> 25521354

Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.

Jessica Tay-Sontheimer1, Laura M Shireman, Richard P Beyer, Taurence Senn, Daniela Witten, Robin E Pearce, Andrea Gaedigk, Cletus L Gana Fomban, Justin D Lutz, Nina Isoherranen, Kenneth E Thummel, Oliver Fiehn, J Steven Leeder, Yvonne S Lin.   

Abstract

AIM: We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. PATIENTS &
METHODS: Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for candidate biomarker selection and validation. Global urinary metabolomics was performed using liquid chromatography quadrupole time-of-flight mass spectrometry. Candidate biomarkers were tested in adults receiving fluoxetine, a CYP2D6 inhibitor.
RESULTS: A biomarker, M1 (m/z 444.3102) was correlated with CYP2D6 activity in both the pediatric training and validation sets. Poor metabolizers had undetectable levels of M1, whereas it was present in subjects with other phenotypes. In adult subjects, a 9.56-fold decrease in M1 abundance was observed during CYP2D6 inhibition.
CONCLUSION: Identification and validation of M1 may provide a noninvasive means of CYP2D6 phenotyping.

Entities:  

Keywords:  CYP2D6; biomarker; clinical; dextromethorphan; endogenous; fluoxetine; metabolomics; pediatric; phenotype

Mesh:

Substances:

Year:  2014        PMID: 25521354      PMCID: PMC4486214          DOI: 10.2217/pgs.14.155

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  47 in total

1.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification.

Authors:  Colin A Smith; Elizabeth J Want; Grace O'Maille; Ruben Abagyan; Gary Siuzdak
Journal:  Anal Chem       Date:  2006-02-01       Impact factor: 6.986

2.  The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Authors:  A Gaedigk; S D Simon; R E Pearce; L D Bradford; M J Kennedy; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

3.  The problems in scaling adult drug doses to children.

Authors:  T N Johnson
Journal:  Arch Dis Child       Date:  2007-03-15       Impact factor: 3.791

4.  Improving pediatric dosing through pediatric initiatives: what we have learned.

Authors:  William Rodriguez; Arzu Selen; Debbie Avant; Chandra Chaurasia; Terrie Crescenzi; Gerlie Gieser; Jennifer Di Giacinto; Shiew-Mei Huang; Peter Lee; Lisa Mathis; Dianne Murphy; Shirley Murphy; Rosemary Roberts; Hari Cheryl Sachs; Sandra Suarez; Veneeta Tandon; Ramana S Uppoor
Journal:  Pediatrics       Date:  2008-03       Impact factor: 7.124

5.  Prediction of drug clearance in children from adults: a comparison of several allometric methods.

Authors:  Iftekhar Mahmood
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

6.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain.

Authors:  T Hiroi; W Kishimoto; T Chow; S Imaoka; T Igarashi; Y Funae
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

7.  Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.

Authors:  M J Blake; A Gaedigk; R E Pearce; L R Bomgaars; M L Christensen; C Stowe; L P James; J T Wilson; G L Kearns; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

8.  Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

Authors:  Ai-Ming Yu; Jeffrey R Idle; Linda G Byrd; Kristopher W Krausz; Adrian Küpfer; Frank J Gonzalez
Journal:  Pharmacogenetics       Date:  2003-03

9.  Metabolite profiling in human urine by LC-MS/MS: method optimization and application for glucuronides from dextromethorphan metabolism.

Authors:  Ursula Lutz; Nataly Bittner; Roman W Lutz; Werner K Lutz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-05-03       Impact factor: 3.205

10.  Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.

Authors:  Ai-Ming Yu; Jeffrey R Idle; Tomas Herraiz; Adrian Küpfer; Frank J Gonzalez
Journal:  Pharmacogenetics       Date:  2003-06
View more
  15 in total

Review 1.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

Review 2.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

3.  The Use of Metabolomics to Identify Biological Signatures of Manganese Exposure.

Authors:  Marissa G Baker; Christopher D Simpson; Yvonne S Lin; Laura M Shireman; Noah Seixas
Journal:  Ann Work Expo Health       Date:  2017-05-01       Impact factor: 2.179

4.  The reproducibility of urinary ions in manganese exposed workers.

Authors:  Marissa G Baker; Yvonne S Lin; Christopher D Simpson; Laura M Shireman; Susan Searles Nielsen; Brad A Racette; Noah Seixas
Journal:  J Trace Elem Med Biol       Date:  2018-11-03       Impact factor: 3.849

5.  Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Authors:  Yvonne S Lin; Savannah J Kerr; Timothy Randolph; Laura M Shireman; Tauri Senn; Jeannine S McCune
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

Review 6.  Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling.

Authors:  Gaëlle Magliocco; Frédérique Rodieux; Jules Desmeules; Caroline Flora Samer; Youssef Daali
Journal:  Pediatr Res       Date:  2019-10-10       Impact factor: 3.756

7.  Isolation and Identification of 3,4-Seco-Solanidine-3,4-dioic acid (SSDA) as a Urinary Biomarker of Cytochrome P450 2D6 (CYP2D6) Activity.

Authors:  Andrew C Behrle; Justin Douglas; J Steven Leeder; Leon van Haandel
Journal:  Drug Metab Dispos       Date:  2022-07-25       Impact factor: 3.579

8.  Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.

Authors:  Haeyoung Zhang; Abdul Basit; Chris Wolford; Kuan-Fu Chen; Andrea Gaedigk; Yvonne S Lin; J Steven Leeder; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2020-02-12       Impact factor: 6.875

Review 9.  Recent advances in the ontogeny of drug disposition.

Authors:  Brian D Chapron; Alenka Chapron; J Steven Leeder
Journal:  Br J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.716

10.  Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.

Authors:  Vasudev Kantae; Elke H J Krekels; Michiel J Van Esdonk; Peter Lindenburg; Amy C Harms; Catherijne A J Knibbe; Piet H Van der Graaf; Thomas Hankemeier
Journal:  Metabolomics       Date:  2016-12-19       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.